Suppr超能文献

[糖尿病肾病的治疗]

[Therapy of diabetic nephropathy].

作者信息

Barna István

机构信息

Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Sz. Belgyógyászati Klinika, Budapest.

出版信息

Orv Hetil. 2003 Jan 26;144(4):165-72.

Abstract

It appears to be confirmed by international studies that the development of end-stage nephropathy, cardiovascular mortality and morbidity can be reduced to a large extent by achieving a target blood pressure of 130/85 mmHg in diabetes hypertension and 125/75 mmHg in diabetic nephropathy. Diuretics, beta-blockers, ACE inhibitors and calcium antagonists are all recommended agents with evidence "A" according to both international and national recommendations. The most efficient nephroprotection and simultaneous intensive and efficient blood pressure reduction can be achieved by ACE inhibitors and AT1 receptor blockers as basic agents. It is often required to use combination treatment to achieve the target blood pressure. In the predialysis stage, tight blood pressure control should be completed with balanced glucose metabolism, restricted protein intake, controlled salt and water metabolism, early treatment of metabolic acidosis and preparation for kidney substitution treatment. The patient and the treating physicians should work together in a coordinated way during the complex nephrology, diabetes, cardiology care to slow down the progress of the disease.

摘要

国际研究似乎证实,通过在糖尿病高血压患者中将血压目标控制在130/85 mmHg,在糖尿病肾病患者中将血压目标控制在125/75 mmHg,可在很大程度上降低终末期肾病的发生、心血管疾病的死亡率和发病率。根据国际和国内指南,利尿剂、β受体阻滞剂、ACE抑制剂和钙拮抗剂均为有“A”级证据的推荐药物。ACE抑制剂和AT1受体阻滞剂作为基础药物可实现最有效的肾脏保护并同时进行强化有效的血压降低。通常需要联合治疗才能达到血压目标。在透析前阶段,应在平衡糖代谢、限制蛋白质摄入、控制水盐代谢、早期治疗代谢性酸中毒以及为肾脏替代治疗做准备的同时,严格控制血压。在复杂的肾脏病、糖尿病、心脏病护理过程中,患者和治疗医生应协同合作,以减缓疾病进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验